• Je něco špatně v tomto záznamu ?

Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer

S. Brönimann, U. Lemberger, A. Bruchbacher, SF. Shariat, MR. Hassler,

. 2020 ; 30 (4) : 519-526. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028043

PURPOSE OF REVIEW: The aim of this article is to give an overview of poly(ADP-ribose) polymerase inhibitors (PARPis) trials in prostate cancer and to discuss emerging approaches with potential future clinical implementation in both prostate and urothelial cancer. RECENT FINDINGS: PARPis are a class of drugs that can be applied for the treatment of homologous recombination repair (HRR)-deficient tumors. Tumors are potentially sensitive to PARPi harbor mutations in genes relevant for DNA damage repair, such as BRCA1/2 or ATM, which are present to a significant degree in metastatic prostate and urothelial cancer patients. Several PARPis have been successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer (mCRPC), and olaparib and rucaparib have recently received breakthrough approval in BRCA1/2 mutated mCRPC. Combination treatment of PARPis with androgen-receptor inhibitors or with checkpoint inhibitors and earlier frontline applications are currently being evaluated, and clinical trials enrolling bladder cancer (BCa) patients with HRR deficiency have recently been initiated. SUMMARY: Approximately 10% of mCRPC patients and 34% of metastatic BCa patients have tumors with HRR deficiency and may benefit from PARPi treatment. Correct identification of these patients as well as determining the most adequate time point for drug administration will be key to successful clinical implementation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028043
003      
CZ-PrNML
005      
20210114152848.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MOU.0000000000000776 $2 doi
035    __
$a (PubMed)32427631
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Brönimann, Stephan $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
245    10
$a Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer / $c S. Brönimann, U. Lemberger, A. Bruchbacher, SF. Shariat, MR. Hassler,
520    9_
$a PURPOSE OF REVIEW: The aim of this article is to give an overview of poly(ADP-ribose) polymerase inhibitors (PARPis) trials in prostate cancer and to discuss emerging approaches with potential future clinical implementation in both prostate and urothelial cancer. RECENT FINDINGS: PARPis are a class of drugs that can be applied for the treatment of homologous recombination repair (HRR)-deficient tumors. Tumors are potentially sensitive to PARPi harbor mutations in genes relevant for DNA damage repair, such as BRCA1/2 or ATM, which are present to a significant degree in metastatic prostate and urothelial cancer patients. Several PARPis have been successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer (mCRPC), and olaparib and rucaparib have recently received breakthrough approval in BRCA1/2 mutated mCRPC. Combination treatment of PARPis with androgen-receptor inhibitors or with checkpoint inhibitors and earlier frontline applications are currently being evaluated, and clinical trials enrolling bladder cancer (BCa) patients with HRR deficiency have recently been initiated. SUMMARY: Approximately 10% of mCRPC patients and 34% of metastatic BCa patients have tumors with HRR deficiency and may benefit from PARPi treatment. Correct identification of these patients as well as determining the most adequate time point for drug administration will be key to successful clinical implementation.
650    _2
$a karcinom z přechodných buněk $7 D002295
650    _2
$a poškození DNA $7 D004249
650    _2
$a inhibitory enzymů $x terapeutické užití $7 D004791
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a inhibitory syntézy nukleových kyselin $x terapeutické užití $7 D019384
650    _2
$a PARP inhibitory $x terapeutické užití $7 D000067856
650    _2
$a nádory prostaty $x farmakoterapie $x patologie $7 D011471
650    _2
$a nádory močového měchýře $x farmakoterapie $x patologie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Lemberger, Ursula $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
700    1_
$a Bruchbacher, Andreas $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Departments of Urology, Weill Cornell Medical College, New York, New York. Department of Urology, University of Texas Southwestern, Dallas, Texas, USA. Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic. Institute for Urology and Reproductive Health, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. Department of Urology, University of Jordan, Amman, Jordan. European Association of Urology Research Foundation, Arnhem, The Netherlands.
700    1_
$a Hassler, Melanie R $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
773    0_
$w MED00001296 $t Current opinion in urology $x 1473-6586 $g Roč. 30, č. 4 (2020), s. 519-526
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32427631 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152846 $b ABA008
999    __
$a ok $b bmc $g 1608378 $s 1119223
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 30 $c 4 $d 519-526 $e - $i 1473-6586 $m Current opinion in urology $n Curr Opin Urol $x MED00001296
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace